AcelRx Pharma (NASDAQ: ACRX) reported Q3 EPS of ($0.28), $0.01 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.22 million.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.